Literature DB >> 357068

Steady-state kinetics of valproic acid in epileptic patients.

J Bruni, B J Wilder, L J Willmore, R J Perchalski, H J Villarreal.   

Abstract

Pharmacokinetic evaluation and prediction were carried out in 20 epileptic patients. Using conventional pharmacokinetic techniques and a one-compartment model, predicted and observed valproic acid plasma concentrations were compared. Valproic acid assay was performed by gas-liquid chromatography. There was good agreement between predicted and observed plasma concentrations. Most patients had predicted half-lives (t1/2s) of 6 to 8 hr, independent of the plasma concentration of valproic acid. Five patients had predicted t1/2s of 12 hr. The correlation between dose and plasma level was poor. Most patients had valproic acid plasma levels between 55 and 100 microgram/ml. Administration of valproic acid three times a day with determination of individual plasma concentrations offers a reliable method of monitoring. Constant levels are maintained in individual patients, but there is substantial intersubject variation.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 357068     DOI: 10.1002/cpt1978243324

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  13 in total

1.  Transplacental passage and half-life of sodium valproate in infants born to epileptic mothers.

Authors:  S Kaneko; K Otani; Y Fukushima; T Sato; Y Nomura; Y Ogawa
Journal:  Br J Clin Pharmacol       Date:  1983-04       Impact factor: 4.335

2.  Absorption rate and bioavailability of valproic acid and its sodium from rectal dosage forms.

Authors:  F Moolenaar; W J Greving; T Huizinga
Journal:  Eur J Clin Pharmacol       Date:  1980-04       Impact factor: 2.953

Review 3.  Clinical pharmacokinetics of valproic acid.

Authors:  R Gugler; G E von Unruh
Journal:  Clin Pharmacokinet       Date:  1980 Jan-Feb       Impact factor: 6.447

4.  Pharmacokinetics of sodium valproate in epileptic patients: prediction of maintenance dosage by single-dose study.

Authors:  G J Schapel; R G Beran; C J Doecke; W J O'Reilly; P A Reece; R H Rischbieth; L N Sansom; P E Stanley
Journal:  Eur J Clin Pharmacol       Date:  1980-01       Impact factor: 2.953

5.  Rectal administration of sodium valproate in children.

Authors:  E Scanabissi; D Dal Pozzo; E Franzoni; C Galloni; G Mengoli; R Calivà
Journal:  Ital J Neurol Sci       Date:  1984-06

6.  Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats.

Authors:  S Kojima; M Nadai; K Kitaichi; L Wang; T Nabeshima; T Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

7.  Pharmacokinetics of total and free valproic acid during monotherapy in infants.

Authors:  L Herngren; B Lundberg; A Nergårdh
Journal:  J Neurol       Date:  1991-09       Impact factor: 4.849

8.  Diurnal variations in steady-state plasma concentrations of valproic acid in epileptic patients.

Authors:  P Loiseau; B Cenraud; R H Levy; R Akbaraly; A Brachet-Liermain; M Guyot; P L Morselli
Journal:  Clin Pharmacokinet       Date:  1982 Nov-Dec       Impact factor: 6.447

Review 9.  Concentration-effect relationships of valproic acid.

Authors:  D W Chadwick
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

10.  Distribution of sodium valproate in normal whole blood and in blood from patients with renal or hepatic disease.

Authors:  R J Shirkey; L B Jellett; D C Kappatos; T J Maling; A Macdonald
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.